Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trialIvan Fan-Ngai Hung, Kwok-Yung Yuen, Kwok-Cheung Lung et al.|The Lancet|2020Cited by 1.6k
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV InfectionsHuibin Lv, Chris Ka Pun Mok, Ray T. Y. So et al.|Cell Reports|2020Cited by 450
Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infectionsHuibin Lv, Chris Ka Pun Mok, Nicholas C. Wu et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 101